Trevi Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(34,443) | $(36,496) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 3,835 | 2,671 |
| Operating lease right-of-use assets | 330 | 262 |
| Depreciation and amortization | 113 | 109 |
| Accretion of available-for-sale marketable securities, net | (1,076) | (1,070) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,636) | 2,736 |
| Accrued expenses and other liabilities | (860) | 3,276 |
| Accounts payable | (721) | (194) |
| Net cash used in operating activities | (34,458) | (28,706) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 52,779 | 55,643 |
| Purchases of available-for-sale marketable securities | (116,266) | (53,271) |
| Purchases of property, equipment and leasehold improvements | (12) | (28) |
| Net cash (used in) provided by investing activities | (63,499) | 2,344 |
| Financing activities: | ||
| Proceeds from offering of common stock, net of commissions | 108,154 | — |
| Proceeds from exercises of warrants | 10,757 | — |
| Proceeds from exercises of stock options | 1,854 | 381 |
| Proceeds from disgorgement of beneficial owner's short-swing profits | 725 | — |
| Proceeds from Employee Stock Purchase Plan | 59 | 34 |
| Payments of offering costs | (809) | — |
| Payments of finance lease | (11) | (95) |
| Proceeds from at-the-market sales agreement, net of commissions and allocated fees | — | 9,697 |
| Net cash provided by financing activities | 120,729 | 10,017 |
| Net increase (decrease) in cash and cash equivalents | 22,772 | (16,345) |
| Cash and cash equivalents at beginning of period | 34,097 | 32,397 |
| Cash and cash equivalents at end of period | $56,869 | $16,052 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.